<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05030571</url>
  </required_header>
  <id_info>
    <org_study_id>IRB216/64</org_study_id>
    <nct_id>NCT05030571</nct_id>
  </id_info>
  <brief_title>The Effects of Double Plasma Molecular Adsorption System in Acute on Chronic Liver Failure Patients</brief_title>
  <official_title>The Effects of Double Plasma Molecular Adsorption System in Acute on Chronic Liver Failure Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chulalongkorn University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chulalongkorn University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Acute liver failure patients posed high mortality rate despite receiving standard therapy.&#xD;
      The severity and mortality even higher in patients with underlying liver disease. Acute liver&#xD;
      failure cause hyperinflammatory response in early stage and immunoparalysis in later stage.&#xD;
      The surge of proinflammatory cytokines leads to multiorgan failure and more liver injury.&#xD;
      Subsequent immunoparalysis may lead to lethal secondary infections.&#xD;
&#xD;
      Liver support system had been used in acute and acute ontop chronic liver disease for last&#xD;
      several decades. Double plasma molecular adsorption system (DPMAS) is one of the promising&#xD;
      non-biological liver support system that have been extensively investigated in acute ontop&#xD;
      chronic liver failure from hepatits B viral. DPMAS circuit consist of BS330 (bilirubin&#xD;
      adsorber) and HA330 (Cytokines adsorber). Thus, DPMAS can also remove various cytokines. The&#xD;
      effect of DPMAS on immune function in these patients has not been explored.&#xD;
&#xD;
      Recent randomized controlled trial by Srisawat et al. demonstrated improvement of mHLA-DR in&#xD;
      septic shock patients who received polymyxin B extracorporeal therapy compare to control arm.&#xD;
      Since liver failure show change of immunological profile resemble to sepsis. Investigators&#xD;
      proposed that removal of toxic liver toxins and lethal cytokines by DPMAS will improve&#xD;
      immunological profiles in acute ontop chronic liver failure patients.&#xD;
&#xD;
      Investigators plan to conduct a randomized controlled trial in acute ontop chronic liver&#xD;
      failure patients who admitted to intensive care unit. Investigators plan to compare the&#xD;
      immunomodulatory effects of DPMAS with standard treatments.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 1, 2021</start_date>
  <completion_date type="Anticipated">July 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">July 1, 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Randomized controlled trial</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>mHLA-DR expression</measure>
    <time_frame>7 days</time_frame>
    <description>mHLA-DR expression</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>survival rate</measure>
    <time_frame>28 days</time_frame>
    <description>survival rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reduction of total bilirubin</measure>
    <time_frame>7 days</time_frame>
    <description>Reduction of total bilirubin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>hepatic encephalopathy grading</measure>
    <time_frame>28 days</time_frame>
    <description>hepatic encephalopathy grading</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>subsequent bacterial infection</measure>
    <time_frame>28 days</time_frame>
    <description>subsequent bacterial infection</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CD11b expression</measure>
    <time_frame>7 days</time_frame>
    <description>CD11b expression</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Acute-On-Chronic Liver Failure</condition>
  <condition>Acute on Chronic Hepatic Failure</condition>
  <arm_group>
    <arm_group_label>Intervention</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intervention group will receive DPMAS extracorporeal treatment one session per day for 3 consecutive days plus standard therapy. We plan to use blood flow rate of 100-120 ml/hour with filtration fraction for plasma separation of 25-30%. DPMAS circuit consist of Plasmaflo OP cartridge (Asahi Medical, Tokyo, Japan), Ion exchange resin hemoperfusion cartridge (BS330; Jafron, Zhuhai City, China), and Neutral adsorption resin hemoperfusion cartridge (HA330-II; Jafron, Zhuhai City, China) We do not use any anticoagulant.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard care</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Standard treatment according to EASL Clinical Practical Guidelines on the management of acute (fulminant) liver failure 2017</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>DPMAS</intervention_name>
    <description>DPMAS circuit consist of Plasmaflo OP cartridge (Asahi Medical, Tokyo, Japan), Ion exchange resin hemoperfusion cartridge (BS330; Jafron, Zhuhai City, China), and Neutral adsorption resin hemoperfusion cartridge (HA330-II; Jafron, Zhuhai City, China)</description>
    <arm_group_label>Intervention</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>standard treatment</intervention_name>
    <description>standard treatment according to EASL Clinical Practical Guidelines on the management of acute (fulminant) liver failure 2017.</description>
    <arm_group_label>Intervention</arm_group_label>
    <arm_group_label>Standard care</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age 18 or more&#xD;
&#xD;
          2. Diagnosis of Acute ontop chronic liver failure by Asian Pacific association for the&#xD;
             study of the liver (APASL) criteria&#xD;
&#xD;
          3. Admitted to intensive care unit&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Pregnancy&#xD;
&#xD;
          2. Received steroid treatment&#xD;
&#xD;
          3. Expected dead within 24 hour&#xD;
&#xD;
          4. WBC &lt; 500/mm3&#xD;
&#xD;
          5. Allergy to DPMAS&#xD;
&#xD;
          6. History of organ transplant&#xD;
&#xD;
          7. Terminal illness with do not resuscitation order&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Phatadon Sirivongrangson, MD</last_name>
    <phone>(+66)0852447788</phone>
    <email>phatadon@hotmail.com</email>
  </overall_contact>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>August 26, 2021</study_first_submitted>
  <study_first_submitted_qc>August 26, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 1, 2021</study_first_posted>
  <last_update_submitted>September 2, 2021</last_update_submitted>
  <last_update_submitted_qc>September 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Chulalongkorn University</investigator_affiliation>
    <investigator_full_name>Nattachai Srisawat ,M.D.</investigator_full_name>
    <investigator_title>Faculty of Medicine</investigator_title>
  </responsible_party>
  <keyword>Hemoperfusion</keyword>
  <keyword>Acute-On-Chronic Liver Failure</keyword>
  <keyword>Cytokine adsorbant therapy</keyword>
  <keyword>HA-330</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Failure</mesh_term>
    <mesh_term>Hepatic Insufficiency</mesh_term>
    <mesh_term>End Stage Liver Disease</mesh_term>
    <mesh_term>Acute-On-Chronic Liver Failure</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

